Citi raised the firm’s price target on Tandem Diabetes to $38 from $31 and keeps a Neutral rating on the shares as part of a Q1 earnings preview for the medical technology group. Expectations are “medium-to-high” for solid deliveries, encouraged by new products and pent-up demand, the analyst tells investors in a research note. The firm says that while the group has traded in-line with the market year-to-date, “it doesn’t really tell the current MedTech story.” Citi believes the Q1 reports should set-up the remainder of the year, hurdling tough year-over-year compares, as new products remain in focus. Its top picks remain Boston Scientific (BSX), Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Reddit initiated, Seagate upgraded: Wall Street’s top analyst calls
- Tandem Diabetes upgraded to Buy at Stifel on strong Mobi adoption
- Tandem Diabetes upgraded to Buy from Hold at Stifel
- Tandem Diabetes price target raised to $31 from $25 at Citi
- Tandem Diabetes announces private placement of $250M in convertible senior notes